The discussion was highly informed, with a focus on how we can move the needle in the challenging antibacterial drug discovery arena.
This talk was hosted by CDD, in conjunction with Pew Trusts and moderated by Keystone Symposia CSO, Dr. Thale Jarvis, with an introduction from Dr. Wes Kim, Senior Officer of Pew Trust's Antibiotic Resistance Project.
If you enjoyed this webinar, you will also like others in our series available here.
You'll also find short bios with links to learn more about this webinar's speakers and moderators below.
AJ Campbell is a computational chemist in the Medicinal Chemistry Group of the Stanley Center for Psychiatric Research at the Broad Institute of the Massachusetts Institute of Technology and Harvard University.
Dr. Campbell is also skilled in drug design and discovery, molecular dynamics, medicinal chemistry, and structural biology.
Cheryl Quinn was Director of Antibacterial Biology at Pfizer and a senior executive at several biotechnology companies focusing on novel antibacterials and antifungals discovery.
An active reviewer for NIH study sections for over 10 years, Dr. Quinn has also led business efforts, culminating in her tenure as CEO of ImmuVen Inc., a T-cell receptor-based technology company. She is an inventor on 42 issued patents.
Thale Jarvis is a member CDD's Customer Advisory Board and is currently CSO at Keystone Symposia. Dr. Jarvis is also Co-Founder, Science Advisor and Vice President of R&D at Crestone, working on C. difficile drug discovery.
Dr. Jarvis is a co-author of 40 publications and a co-inventor of over a dozen issued patents.
Wes Kim is Senior Officer, Innovation for the Antibiotic Resistance Project at the Pew Charitable Trusts where he leads efforts to spur the innovation of new antibiotics for Pew's antibiotic resistance project.
Dr. Kim's work focuses on research and policies that will help to advance antibiotic discovery and development.